Hyman Charles D Sells 20 Shares of Eli Lilly and Company (NYSE:LLY)

Hyman Charles D reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% during the fourth quarter, HoldingsChannel reports. The firm owned 15,403 shares of the company’s stock after selling 20 shares during the period. Hyman Charles D’s holdings in Eli Lilly and Company were worth $8,979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. JB Capital LLC lifted its holdings in Eli Lilly and Company by 12.8% in the third quarter. JB Capital LLC now owns 935 shares of the company’s stock valued at $502,000 after acquiring an additional 106 shares during the period. WealthShield Partners LLC lifted its holdings in Eli Lilly and Company by 134.6% in the third quarter. WealthShield Partners LLC now owns 2,067 shares of the company’s stock valued at $1,110,000 after acquiring an additional 1,186 shares during the period. Verdence Capital Advisors LLC increased its position in Eli Lilly and Company by 27.1% in the third quarter. Verdence Capital Advisors LLC now owns 7,266 shares of the company’s stock worth $3,903,000 after buying an additional 1,551 shares in the last quarter. BluePath Capital Management LLC purchased a new stake in Eli Lilly and Company in the third quarter worth about $384,000. Finally, Mackenzie Financial Corp increased its position in Eli Lilly and Company by 5.0% in the third quarter. Mackenzie Financial Corp now owns 339,719 shares of the company’s stock worth $178,417,000 after buying an additional 16,045 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Barclays upped their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, Truist Financial increased their target price on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Trading Down 0.4 %

Shares of NYSE:LLY traded down $2.77 during trading on Wednesday, hitting $775.00. The company had a trading volume of 2,010,705 shares, compared to its average volume of 3,076,480. The stock has a market cap of $736.56 billion, a price-to-earnings ratio of 114.14, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37. Eli Lilly and Company has a one year low of $419.80 and a one year high of $800.78. The company has a fifty day simple moving average of $761.22 and a two-hundred day simple moving average of $674.88. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same period last year, the company earned $1.62 EPS. The company’s revenue for the quarter was up 26.0% on a year-over-year basis. As a group, equities analysts forecast that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.